A Phase 2A, Randomized, Double-Blind, Placebo Controlled Study Investigating The Safety Of Ritlecitinib (Pf-06651600) In Adult Participants With Alopecia Areata
Last Updated:
02/17/2021
Status:
Active/Fully Enrolled
Country:
United States
Eligibility:
Ages 18-50; diagnosed with alopecia areata (at least 25% hair loss due to AA)
Drug:
PF-06651600
Administration:
Oral
Sponsor:
Pfizer
Link:
A clinical research study is currently looking for adults with alopecia areata who have lost 25% or more of the hair on their head to participate in a study of an oral investigational medication. The study will explore whether the study drug is safe and can help patients with alopecia areata regrow their hair.
The study will run for approximately 26 months. This includes up to a 5-week screening period, a 9-month treatment period where the investigational medication is compared to an inactive placebo, a 15-month treatment period where all study participants take the investigational medication, plus a 4-week follow-up period.
You may qualify to participate if you:
- are 18-50 years of age
- have been diagnosed with alopecia areata
- have at least 25% scalp hair loss*